Uterine papillary serous carcinoma: study of 19 cases.
OBJECTIVE
Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial carcinoma that histologically and clinically resembles ovarian papillary serous carcinoma. The purpose of this study was to present the conjoined experience of two regional hospitals in the south of Israel (Soroka Medical Center, Beer-Sheva and Kaplan Hospital, Rehovot) of handling this tumour.


METHODS
Data from the files of 19 patients with UPSC who were managed at these hospitals between July 1991 and June 1997 were evaluated.


RESULTS
The three-year survival rate was 57.3% overall; 83.3% for Stage I and 21.2% for Stages II, III, and IV combined (P<0.02). Eighteen patients had primary surgery which included total abdominal hysterectomy and bilateral salpingo-oophorectomy and 15 (83.3%) of them received postoperative adjuvant therapy which included radiotherapy and/or systemic chemotherapy.


CONCLUSIONS
The prognosis of patients with UPSC is worse than that of patients with other forms of endometrial carcinoma. Primary surgery comprised of total abdominal hysterectomy, bilateral salpingo-oophorectomy and staging is the mainstay of treatment. The type of postoperative treatment is not consistent. By and large, adjuvant pelvic radiotherapy is usually given in early-stage disease and adjuvant systemic chemotherapy is usually prescribed in advanced-stage disease.
Piura
B
B
Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. piura@bgumail.bgu.ac.il
Meirovitz
M
M
Shmulman
M
M
Yanai-Inbar
I
I
Cohen
Y
Y
Dgani
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D003131:Combined Modality Therapy; D018283:Cystadenocarcinoma, Papillary / Q000175:diagnosis* / Q000628:therapy; D005006:Ethnicity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000628:therapy